[Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
Regulation (EC) No. 1394/2007 has created a new legal framework for advanced therapy medicinal products (gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products). The Regulation is directly applicable in the Member States of the European Union and, in principle, requires no incorporation into national law. However, the amendment of Directive 2001/83/EC, which results from Regulation (EC) No. 1394/2007, has created a need for incorporation into and amendment of the German Medicinal Products Act. This is one of the objectives of the 15th amendment of the German Medicinal Products Act. In particular, the definition "advanced therapy medicinal products" and the special provisions for advanced therapy medicinal products prepared on a non-routine basis, which are based on the special provisions contained in Art. 28 No. 2 of Regulation (EC) No. 1394/2007, are to be incorporated into the German Medicinal Products Act. These special provisions will be explained in detail.
Dwenger
A
A
Bundesministerium für Gesundheit, Rochusstr. 1, 53123, Bonn.
Strassburger
J
J
Schwerdtfeger
W
W
D017690:Cell Transplantation / Q000331:legislation & jurisprudence*; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence; D015316:Genetic Therapy / Q000331:legislation & jurisprudence*; D005858:Germany; D017408:Guidelines as Topic; D006801:Humans; D009313:National Health Programs / Q000331:legislation & jurisprudence*; D023822:Tissue Engineering / Q000331:legislation & jurisprudence*